Telitacicept add-on therapy in refractory idiopathic inflammatory myopathy: insights from a pilot study
Authors' conclusion
Telitacicept demonstrated effectiveness in treating refractory inflammatory myopathy, contributing to a significant reduction in steroid dosage among the patients.
Study context
- Population
- Adults with refractory idiopathic inflammatory myopathy (IIM) treated January 2023 to January 2024
- Participants
- 11 adults
- Comparison
- Telitacicept add-on to conventional treatment, baseline vs last visit
- Telitaciceptn = 11
- Outcome
- Clinical response by ACR/EULAR criteria for minimal, moderate and major improvement in the Total Improvement Score
Methodological detailssingle-group, before-after comparison
- Single-group
- Before-after comparison
Main finding
As reported in the abstract
Clinical response by ACR/EULAR criteria
- Improvement in all patients according to ACR/EULAR criteria
Further findings
Prednisone dosage, baseline to last visit
- Baseline
- 27.05 (12.47) mg
- Last visit
- 12.05 (7.32) mg
- Significant reduction
- P < 0.005
MMT-8 score, baseline to last visit
- Baseline
- 109.18 (14.18)
- Last visit
- 137.64 (15.28)
- Improvement
- P < 0.005
Creatine kinase level, baseline to last visit
- Baseline
- 2670.27 (2675.00) U/l
- Last visit
- 561.09 (754.09) U/l
- Reduction
- P < 0.05
Original publication
Telitacicept add-on therapy in refractory idiopathic inflammatory myopathy: insights from a pilot study. Rheumatology (Oxford). Published 4 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →